Evidence map›Paper›PMID 30108956›Full record

ArticleMedChemComm2018

Studies towards elucidating the potential of 5,10,15,20-tetrakis(

Mohini Guleria, Chandan Kumar, Tapas Das, Jeyachitra Amirdhanayagam, Rohit Sharma, Haladhar D Sarma, Ashutosh Dash

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mohini GuleriaRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.
Chandan KumarRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.ORCID 0000-0002-2214-9792
Tapas DasRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.ORCID 0000-0003-2877-0683
Jeyachitra AmirdhanayagamRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.
Rohit SharmaRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.
Haladhar D SarmaRadiation Biology and Health Sciences Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India.ORCID 0000-0001-7168-4487
Ashutosh DashRadiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . Email: tdas@barc.gov.in ; ; Tel: +91 22 2559 0613.
Bhabha Atomic Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Porphyrins, owing to their inherent tendency to accumulate in tumorous lesions, are considered suitable for developing agents for theranostic applications involving tumor diagnosis and targeted tumor therapy. The aim of the present work is to study the potential of a porphyrin derivative namely, 5,10,15,20-tetrakis(

Identifiers

PMID30108956
PMCPMC6072032
OpenAlexW2785987874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.